Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 May;84(9):1235–1241. doi: 10.1054/bjoc.2000.1735

Transcriptional dysregulation of the p73L / p63 / p51 / p40 / KET gene in human squamous cell carcinomas: expression of Δ Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51

M Senoo 1,5, I Tsuchiya 2, Y Matsumura 1, T Mori 3, Y Saito 2, H Kato 4, T Okamoto 3, S Habu 1,5
PMCID: PMC2363892  PMID: 11336476

Abstract

We have recently identified a second p53 -related p73L gene, also referred to as p63 / p51 / p40 / KET gene, which encodes the 2 major isoforms p73L and p51 resulting from different exon usage at their amino terminal regions. Although p73L and p51 are suspected to play oncogenic and tumour suppressive roles in mammalian cells, respectively, no evidence of linkage between the expression of these isoforms and human cancers has been reported so far. In this study, we first investigated the expression profile of p51 and p73L in various human tumour cell lines and found that a novel isoform, termed ΔNp73L, was predominantly expressed in squamous cell carcinomas. The expression profile of ΔNp73L/p73L/p51 in primary human skin cancer specimens showed that the expression of p51 was frequently lost (62%) but was detected in all normal skin samples. In p51-expressing skin cancers, ΔNp73L expression was associated at a high frequency (75%) though it was not detected in normal skin tissues. Transient co-transfection data indicate the possibility that ΔNp73L can inhibit p53-, and more preferentially, p51-mediated transactivation. These data suggest that the loss of expression of p51 and/or the expression of ΔNp73L might contribute to the pathogenesis of human squamous cell carcinomas. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: p53 homologue, p73L, ΔNp73L, squamous cell carcinoma

Full Text

The Full Text of this article is available as a PDF (135.6 KB).

Footnotes

GenBank accession number for DNp73L: |AB042841.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Augustin M., Bamberger C., Paul D., Schmale H. Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm Genome. 1998 Nov;9(11):899–902. doi: 10.1007/s003359900891. [DOI] [PubMed] [Google Scholar]
  2. De Laurenzi V., Costanzo A., Barcaroli D., Terrinoni A., Falco M., Annicchiarico-Petruzzelli M., Levrero M., Melino G. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med. 1998 Nov 2;188(9):1763–1768. doi: 10.1084/jem.188.9.1763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Di Como C. J., Gaiddon C., Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol. 1999 Feb;19(2):1438–1449. doi: 10.1128/mcb.19.2.1438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dobbelstein M., Wienzek S., König C., Roth J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene. 1999 Mar 25;18(12):2101–2106. doi: 10.1038/sj.onc.1202512. [DOI] [PubMed] [Google Scholar]
  5. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  6. Hagiwara K., McMenamin M. G., Miura K., Harris C. C. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res. 1999 Sep 1;59(17):4165–4169. [PubMed] [Google Scholar]
  7. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., Harris C. C., Montesano R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998 Jan 1;26(1):205–213. doi: 10.1093/nar/26.1.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  9. Jost C. A., Marin M. C., Kaelin W. G., Jr p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997 Sep 11;389(6647):191–194. doi: 10.1038/38298. [DOI] [PubMed] [Google Scholar]
  10. Kaelin W. G., Jr The emerging p53 gene family. J Natl Cancer Inst. 1999 Apr 7;91(7):594–598. doi: 10.1093/jnci/91.7.594. [DOI] [PubMed] [Google Scholar]
  11. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J. C., Valent A., Minty A., Chalon P., Lelias J. M., Dumont X. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997 Aug 22;90(4):809–819. doi: 10.1016/s0092-8674(00)80540-1. [DOI] [PubMed] [Google Scholar]
  12. Kanda T., Segawa K., Ohuchi N., Mori S., Ito Y. Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site. Mol Cell Biol. 1994 Apr;14(4):2651–2663. doi: 10.1128/mcb.14.4.2651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  14. Marin M. C., Jost C. A., Irwin M. S., DeCaprio J. A., Caput D., Kaelin W. G., Jr Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol. 1998 Nov;18(11):6316–6324. doi: 10.1128/mcb.18.11.6316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nishi H., Isaka K., Sagawa Y., Usuda S., Fujito A., Ito H., Senoo M., Kato H., Takayama M. Mutation and transcription analyses of the p63 gene in cervical carcinoma. Int J Oncol. 1999 Dec;15(6):1149–1153. doi: 10.3892/ijo.15.6.1149. [DOI] [PubMed] [Google Scholar]
  16. Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I., Ikawa Y., Nimura Y., Nakagawara A., Obinata M. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med. 1998 Jul;4(7):839–843. doi: 10.1038/nm0798-839. [DOI] [PubMed] [Google Scholar]
  17. Park B. J., Lee S. J., Kim J. I., Lee S. J., Lee C. H., Chang S. G., Park J. H., Chi S. G. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res. 2000 Jul 1;60(13):3370–3374. [PubMed] [Google Scholar]
  18. Parsa R., Yang A., McKeon F., Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol. 1999 Dec;113(6):1099–1105. doi: 10.1046/j.1523-1747.1999.00780.x. [DOI] [PubMed] [Google Scholar]
  19. Prives C., Hall P. A. The p53 pathway. J Pathol. 1999 Jan;187(1):112–126. doi: 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  20. Schmale H., Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene. 1997 Sep;15(11):1363–1367. doi: 10.1038/sj.onc.1201500. [DOI] [PubMed] [Google Scholar]
  21. Senoo M., Seki N., Ohira M., Sugano S., Watanabe M., Inuzuka S., Okamoto T., Tachibana M., Tanaka T., Shinkai Y. A second p53-related protein, p73L, with high homology to p73. Biochem Biophys Res Commun. 1998 Jul 30;248(3):603–607. doi: 10.1006/bbrc.1998.9013. [DOI] [PubMed] [Google Scholar]
  22. Steegenga W. T., Shvarts A., Riteco N., Bos J. L., Jochemsen A. G. Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and E4orf6 proteins. Mol Cell Biol. 1999 May;19(5):3885–3894. doi: 10.1128/mcb.19.5.3885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sunahara M., Shishikura T., Takahashi M., Todo S., Yamamoto N., Kimura H., Kato S., Ishioka C., Ikawa S., Ikawa Y. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer. Oncogene. 1999 Jun 24;18(25):3761–3765. doi: 10.1038/sj.onc.1202972. [DOI] [PubMed] [Google Scholar]
  24. Trink B., Okami K., Wu L., Sriuranpong V., Jen J., Sidransky D. A new human p53 homologue. Nat Med. 1998 Jul;4(7):747–748. doi: 10.1038/nm0798-747. [DOI] [PubMed] [Google Scholar]
  25. Ueda Y., Hijikata M., Takagi S., Chiba T., Shimotohno K. New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene. 1999 Sep 2;18(35):4993–4998. doi: 10.1038/sj.onc.1202817. [DOI] [PubMed] [Google Scholar]
  26. Weinberg R. Tumor suppressor genes. Neuron. 1993 Aug;11(2):191–196. doi: 10.1016/0896-6273(93)90177-s. [DOI] [PubMed] [Google Scholar]
  27. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M. D., Dötsch V., Andrews N. C., Caput D., McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998 Sep;2(3):305–316. doi: 10.1016/s1097-2765(00)80275-0. [DOI] [PubMed] [Google Scholar]
  28. Zeng X., Chen L., Jost C. A., Maya R., Keller D., Wang X., Kaelin W. G., Jr, Oren M., Chen J., Lu H. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol. 1999 May;19(5):3257–3266. doi: 10.1128/mcb.19.5.3257. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES